AOD-9604 + CJC-1295 + Ipamorelin (12mg Blend Vial)

01 · At a glance

Quickstart Highlights

The AOD-9604 6mg + CJC-1295 3mg + Ipamorelin 3mg (12mg Blend Vial) dosage protocol is designed for research purposes to explore potential metabolic, regenerative, and fat oxidation effects via daily subcutaneous injections. Typical starting dose: 400 mcg daily, with gradual titration up to 1.2 mg daily Single daily injection ensures ease of use and accurate dosing Titration phases allow for safe adjustment based on research parameters Reconstitute with 3 mL bacteriostatic water to achieve a 4 mg/mL solution Store lyophilized vials in the freezer; reconstituted solution must be refrigerated

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Approach (Reconstituted with 3 mL = 4 mg/mL)

Reference dose shown on this page: See guide.

Reconstitution Steps

1. Confirm the vial amount, unit, and diluent amount before entering values in the calculator.
2. Add diluent slowly down the inner wall of the vial when reconstitution is appropriate for the compound.
3. Swirl or roll gently until dissolved; avoid shaking unless the product instructions specifically say otherwise.
4. Label the vial with the date and concentration, then store according to the protocol and product instructions.

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Protocol Overview

• Goal: Investigate metabolic support, fat oxidation, and regenerative properties.
• Schedule: Daily subcutaneous injections over a 12-week cycle.
• Dose Range: Start at 400 mcg daily, increasing to 1.2 mg daily.
• Reconstitution: Reconstitute with 3 mL to achieve a 4 mg/mL solution.
• Storage: Freeze lyophilized vials; refrigerate reconstituted solution at 2–8°C.

Dosing Protocol

• This protocol involves a single daily injection with gradual titration: Daily Dose: Begin with 400 mcg (10 units) and increase to 1,200 mcg (30 units) as tolerated.
• Frequency: Once daily, preferably at the same time each day.
• Cycle Length: 12 weeks (adjustable based on research parameters).
• Note: Ensure consistent dosing intervals and accurate measurement using a 100-unit insulin syringe.

Storage Instructions

• Proper storage ensures peptide integrity.
• Lyophilized: Store in the freezer (−20°C) until reconstitution.
• Reconstituted: Keep in the refrigerator at 2–8°C.
• Use within 30 days of reconstitution; avoid repeated freeze-thaw cycles.

04 · Good to know

Important Notes

• Practical tips to enhance safety and efficacy.
• Always use new, sterile insulin syringes & rotate injection sites.
• Maintain consistent injection times for optimal results.
• Monitor for any adverse reactions and consult with a professional if concerns arise.
• Ensure accurate dosing; if injections are below ~10 units, consider using a smaller insulin syringe.

05 · How it works

How This Works

The AOD-9604 6mg + CJC-1295 3mg + Ipamorelin 3mg (12mg Blend Vial) dosage protocol is designed for research purposes to explore potential metabolic, regenerative, and fat oxidation effects via daily subcutaneous injections.

Typical starting dose: 400 mcg daily, with gradual titration up to 1.2 mg daily Single daily injection ensures ease of use and accurate dosing Titration phases allow for safe adjustment based on research parameters Reconstitute with 3 mL bacteriostatic water to achieve a 4 mg/mL solution Store lyophilized vials in the freezer; reconstituted solution must...

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

• Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
• Track body metrics only if they are relevant to the user's goal and approved data sources.
• Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

• AOD-9604 + CJC-1295 + Ipamorelin observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
• This section is not a claim of therapeutic benefit.

08 · Technique

Injection Technique

09 · Evidence

References